Prospective evaluation of genomics-guided off-label treatment

Over the past nine years, DRUP provided opportunities for off-label treatment to more than 1,600 patients with advanced cancers with no remaining standard therapeutic options. This included a substantial proportion (39.1%) of patients with rare…